TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34962901

Group type: EXPERIMENTAL
Intervention: Procedural sedation conducted by nonphysician providers
Number of subjects: 336

Group type: COMPARATOR
Intervention: Procedural sedation conducted by physician providers
Number of subjects: 336
Study: 34963453

Group type: EXPERIMENTAL
Intervention: Nurse-led face-to-face intervention (FOCUS+)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Web-based intervention (iFOCUS)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 936
Study: 34963486

Group type: EXPERIMENTAL
Intervention: hf-tRNS (100-500 Hz) delivered for 20 min with a current intensity of 2 mA and a 1-mA offset twice a day on 5 consecutive weekdays
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham hf-tRNS
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: hf-tRNS
Number of subjects: 144
Study: 34963493

Group type: EXPERIMENTAL
Intervention: Anaesthesiologist-assisted ultrasound-guided erector spinae catheter
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgeon-assisted video-assisted paravertebral catheter
Number of subjects: 80
Study: 34963501

Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 82

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: combined group analysis (tDCS + robotic therapy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: intensive robotic therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: combined intervention (tDCS + robotic therapy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: wrist submovement characteristics
Number of subjects: 82
Study: 34963502

Group type: EXPERIMENTAL
Intervention: Robotic therapy and transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study: 34963563

Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Number of subjects: 156

Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 156
Study: 34963655

Group type: EXPERIMENTAL
Intervention: Universal ASD screening and evaluation process
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Universal ASD screening
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: False-positive ASD screen
Number of subjects: 26
Study: 34964367

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) using a novel PFA system (PulseSelect; Medtronic, Inc)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 38
Study: 34964890

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 7573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7573
Study: 34964932

Group type: EXPERIMENTAL
Intervention: Atovaquone treatment (Cohort 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Cohort 2)
Number of subjects: 30
Study: 34964996

Group type: EXPERIMENTAL
Intervention: MammaPrint
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: BluePrint
Number of subjects: 121
Study: 34965032

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination
Number of subjects: 49
Study: 34965620

Group type: EXPERIMENTAL
Intervention: Patients with chronic periodontitis and type 2 diabetes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 40
Study: 34965883

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Androgens for long-term prophylaxis
Number of subjects: 119
Study: 34965890

Group type: EXPERIMENTAL
Intervention: Selinexor with carboplatin, doxorubicin, and cyclophosphamide (DC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Selinexor with irinotecan, fluorouracil, and folinic acid (FOLFIRI)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Selinexor with irinotecan, capecitabine, and oxaliplatin (XELOX)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of oral selinexor with different standard chemotherapies
Number of subjects: 19
Study: 34965951

Group type: EXPERIMENTAL
Intervention: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in STS cohort
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in ovarian carcinoma cohort
Number of subjects: 40
Study: 34966107

Group type: EXPERIMENTAL
Intervention: Imlifidase-generated single-cleaved IgG (scIgG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentrated scIgG from a highly HLA-sensitized individual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imlifidase treatment
Number of subjects: 0
Study: 34966186

Group type: EXPERIMENTAL
Intervention: Water supplementation
Number of subjects: 31
Study: 34966256

Group type: EXPERIMENTAL
Intervention: Baseline predictors of clinical progression in early PD
Number of subjects: 0
Study: 34966299

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34966645

Group type: EXPERIMENTAL
Intervention: Non-invasive score using noncontrast-enhanced MRI (CHESS-DIS score)
Number of subjects: 149
Study: 34966667

Group type: EXPERIMENTAL
Intervention: Home-based physical activity program during neoadjuvant chemotherapy (NACT) combining aerobic and strengthening exercises.
Number of subjects: 70
Study: 34966795

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34966798

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard treatment not specified)
Number of subjects: 0
Study: 34966799

Group type: EXPERIMENTAL
Intervention: Anatomical Assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pullback Resting full-cycle ratio (RFR) Measurement
Number of subjects: 0
Study: 34966951

Group type: EXPERIMENTAL
Intervention: End-expiratory lung volume measured with volumetric capnography (EELV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34966981

Group type: EXPERIMENTAL
Intervention: Anxiety disorders group (N = 103)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: OCD group (N = 118)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Healthy controls (N = 28)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Adolescent participants (ages 13-17 years) in anxiety disorders group
Number of subjects: 409
Study: 34967448

Group type: EXPERIMENTAL
Intervention: Extraction of the primary canine
Number of subjects: 199

Group type: COMPARATOR
Intervention: No extraction (control)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Double primary tooth extraction
Number of subjects: 199

Group type: COMPARATOR
Intervention: Single primary tooth extraction
Number of subjects: 199
Study: 34967504

Group type: EXPERIMENTAL
Intervention: Same-day ART (SDART)
Number of subjects: 1904
Study: 34967751

Group type: EXPERIMENTAL
Intervention: Tablet-based cognitive battery (Adaptive Cognitive Evaluation [ACE])
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tablet-based cognitive battery (ACE)
Number of subjects: 53
Study: 34967755

Group type: EXPERIMENTAL
Intervention: MAPS (Motivation And Problem Solving)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 202
Study: 34967894

Group type: EXPERIMENTAL
Intervention: Iron-fortified rice extruded with citric acid (CA) and trisodium citrate (TSC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Iron-fortified rice extruded without CA/TSC
Number of subjects: 22
Study: 34967916

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg Q2W from Week 12 to Week 20
Number of subjects: 12
Study: 34968102

Group type: EXPERIMENTAL
Intervention: General cognitive training (two interventions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific instrumental activities of daily living (IADL) training (one intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 34968106

Group type: EXPERIMENTAL
Intervention: varenicline (1 mg/bid)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: varenicline (1 mg/bid) plus naltrexone (50 mg/day)
Number of subjects: 115
Study: 34968756

Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 1459

Group type: COMPARATOR
Intervention: Aflibercept 2 mg
Number of subjects: 1459
Study: 34969046

Group type: EXPERIMENTAL
Intervention: I-Score intervention via smartphone application (Opal)
Number of subjects: 32
Study: 34969173

Group type: EXPERIMENTAL
Intervention: RCT-HF risk factors (hypertension, stable angina, unstable angina, myocardial infarction, diabetes)
Number of subjects: 170885

Group type: EXPERIMENTAL
Intervention: RCT-CVD risk factors (smoking, obesity)
Number of subjects: 170885

Group type: COMPARATOR
Intervention: No RCT-HF RFs
Number of subjects: 170885

Group type: COMPARATOR
Intervention: No RCT-CVD RFs
Number of subjects: 170885

Group type: COMPARATOR
Intervention: No RF or only RCT-0 RFs
Number of subjects: 170885
Study: 34969254

Group type: EXPERIMENTAL
Intervention: Vaginal ring designs (four designs presented via a visual tool)
Number of subjects: 0
Study: 34969397

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CMR myocarditis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Discharge status
Number of subjects: 111
Study: 34969408

Group type: EXPERIMENTAL
Intervention: Optimized questionnaire measuring sedentary time
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Original and optimized questionnaires
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Optimized questionnaire
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Developed questionnaire
Number of subjects: 131
Study: 34969496

Group type: EXPERIMENTAL
Intervention: Automated speech analysis technology (HearO)
Number of subjects: 40
Study: 34969647

Group type: EXPERIMENTAL
Intervention: Multidisciplinary palliative care approach (physiotherapist, psychologist, pulmonologists, palliative care doctors)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multidisciplinary palliative care approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 34969664

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for insomnia (CBT-I), 5 sessions, gold-standard treatment.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for insomnia (CBT-I)
Number of subjects: 20
Study: 34969665

Group type: EXPERIMENTAL
Intervention: Indigo naturalis (IN) 500 mg/day or 1.5 g/day for 8 weeks
Number of subjects: 11
Study: 34970227

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) group
Number of subjects: 5154

Group type: COMPARATOR
Intervention: Non-Diabetes Mellitus (non-DM) group
Number of subjects: 5154
Study: 34970476

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study: 34970487

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab plus nivolumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 10
Study: 34970731

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 2257

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 2257

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 2257

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 2257

Group type: COMPARATOR
Intervention: Pooled placebo
Number of subjects: 2257
Study: 34970744

Group type: EXPERIMENTAL
Intervention: Free epithelialized gingival/mucosal grafts (FEGs) used for KT augmentation
Number of subjects: 52
Study: 34970774

Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Incorporation of serum C-reactive protein and albumin levels
Number of subjects: 59
Study: 34970860

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34971075

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 37
Study: 34971362

Group type: EXPERIMENTAL
Intervention: Vaccinated men (HYPER2)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Unvaccinated men (HYPER1)
Number of subjects: 327
Study: 34971582

Group type: EXPERIMENTAL
Intervention: Older patients (aged ≥15 years)
Number of subjects: 1907

Group type: COMPARATOR
Intervention: Younger patients (aged <15 years)
Number of subjects: 1907

Group type: EXPERIMENTAL
Intervention: Older patients with non-mixed cellularity histology
Number of subjects: 1907

Group type: EXPERIMENTAL
Intervention: Older patients with mixed cellularity
Number of subjects: 1907

Group type: COMPARATOR
Intervention: Younger patients with mixed cellularity
Number of subjects: 1907

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 1907
Study: 34971971

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zol) in conjunction with radiation therapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zol) + RT
Number of subjects: 0

Group type: COMPARATOR
Intervention: FDPS overexpression in PDAC tissues and cells
Number of subjects: 0
Study: 34972140

Group type: EXPERIMENTAL
Intervention: Digital therapeutic intervention targeting midline frontal theta (MFT) circuitry for 4 weeks on an iPad
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Digital therapeutic intervention targeting midline frontal theta (MFT) circuitry
Number of subjects: 25
Study: 34972202

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus dinaciclib
Number of subjects: 72
Study: 34972234

Group type: EXPERIMENTAL
Intervention: Healthy siblings of children with rare congenital surgical diseases
Number of subjects: 81
Study: 34972260

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: FF/VI 100/25mcg
Number of subjects: 0
Study: 34972609

Group type: EXPERIMENTAL
Intervention: Volume challenge (200 ml saline in 20 s)
Number of subjects: 32
Study: 34972665

Group type: EXPERIMENTAL
Intervention: NIRS-IVUS imaging at baseline
Number of subjects: 73

Group type: COMPARATOR
Intervention: No imaging at baseline
Number of subjects: 73
Study: 34972769

Group type: EXPERIMENTAL
Intervention: Combined assessment of circulating biomarkers (circulating tumour DNA, cell-free methylated DNA, circulating proteins) and radiomic variables
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Blood and urine samples from patients with stage I-IIA BC
Number of subjects: 750

Group type: COMPARATOR
Intervention: Blood and urine samples from patients with benign lesions and healthy controls
Number of subjects: 750
Study: 34972822

Group type: EXPERIMENTAL
Intervention: Iron supplementation (part of a double-blind, randomized iron intervention trial)
Number of subjects: 616
Study: 34972827

Group type: EXPERIMENTAL
Intervention: Real time laser-doppler flowmetry (LDF) and white light spectrophotometry (WLS) used for assessment of microcirculatory oxygen delivery and uptake before and after forearm ischemia.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 60
Study: 34973077

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5→10 mg BID (Dose-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib 5 mg BID (Stay-on 5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10→5 mg BID (Dose-down)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib 10 mg BID (Stay-on 10)
Number of subjects: 0
Study: 34973207

Group type: EXPERIMENTAL
Intervention: Etonogestrel implants
Number of subjects: 20
Study: 34973418

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) using superDimension navigation system versions 6.3 to 7.1
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB)
Number of subjects: 1388
Study: 34973601

Group type: EXPERIMENTAL
Intervention: Racemic ketamine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34974364

Group type: EXPERIMENTAL
Intervention: CT-FFR-D (diastolic phase)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CT-FFR-S (systolic phase)
Number of subjects: 151
Study: 34974453

Group type: EXPERIMENTAL
Intervention: Homologous third dose of inactivated whole-virion vaccine
Number of subjects: 0
Study: 34974510

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg) with a treat-and-extend regimen
Number of subjects: 45
Study: 34974659

Group type: EXPERIMENTAL
Intervention: Precautionary behavior during COVID-19 pandemic
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Higher CCI status
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Education and income levels
Number of subjects: 306
Study: 34974918

Group type: EXPERIMENTAL
Intervention: Computer-facilitated Screening and provider Brief Advice (cSBA)
Number of subjects: 2096

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 2096
Study: 34975369

Group type: EXPERIMENTAL
Intervention: Preoperative chronic pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preoperative chronic pain
Number of subjects: 0
Study: 34975713

Group type: EXPERIMENTAL
Intervention: FES-assisted cycling training (40 min/session, 3-5 sessions/week for 20 sessions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FES-assisted cycling training
Number of subjects: 15
Study: 34975844

Group type: EXPERIMENTAL
Intervention: Allogeneic Vγ9Vδ2 T-cell therapy adjunct with anti-TB drugs
Number of subjects: 8
Study: 34976286

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (24 U)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 34976290

Group type: EXPERIMENTAL
Intervention: VP-102 (Cantharidin, 0.7% w/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 34976630

Group type: EXPERIMENTAL
Intervention: Self-HPV (home-based Human Papillomavirus self-sampling)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Dr-HPV (HPV performed by the physician)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Self-HPV
Number of subjects: 127
Study: 34976830

Group type: EXPERIMENTAL
Intervention: AdHER2 DC vaccine
Number of subjects: 33
Study: 34977109

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study: 34977512

Group type: EXPERIMENTAL
Intervention: Fresh lemon juice supplementation (60 mL twice daily)
Number of subjects: 203

Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 203
Study: 34977516

Group type: EXPERIMENTAL
Intervention: Tele-Gaming
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Self-Gaming
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 193
Study: 34977519

Group type: EXPERIMENTAL
Intervention: Pegbelfermin (PGBF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 34977602

Group type: EXPERIMENTAL
Intervention: Two doses of SARS-CoV-2 vaccines
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Three doses of SARS-CoV-2 vaccines
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls receiving two doses of SARS-CoV-2 vaccines
Number of subjects: 90
Study: 34977838

Group type: EXPERIMENTAL
Intervention: Quality Measures based on WHO Standards
Number of subjects: 21027
Study: 34977972

Group type: EXPERIMENTAL
Intervention: Erdafitinib 6-mg/day
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Erdafitinib 8-mg/day
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Erdafitinib (both doses)
Number of subjects: 156
Study: 34977985

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 122
Study: 34977986

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 107
Study: 34978027

Group type: EXPERIMENTAL
Intervention: Eliapixant (P2X3 receptor antagonist)
Number of subjects: 0
Study: 34978544

Group type: EXPERIMENTAL
Intervention: Support person present
Number of subjects: 76

Group type: COMPARATOR
Intervention: No support person
Number of subjects: 76
Study: 34978580

Group type: EXPERIMENTAL
Intervention: Post-contrast 3D T1-weighted images using FreeSurfer
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pre-contrast 3D T1-weighted images using FreeSurfer
Number of subjects: 22
Study: 34978654

Group type: EXPERIMENTAL
Intervention: OptiBP™ (optical smartphone application)
Number of subjects: 101
Study: 34978656

Group type: EXPERIMENTAL
Intervention: ZHF sensors
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DS sensors
Number of subjects: 60
Study: 34978890

Group type: EXPERIMENTAL
Intervention: Monthly long-acting cabotegravir + rilpivirine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily oral dolutegravir/abacavir/lamivudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting therapy
Number of subjects: 0
Study: 34979020

Group type: EXPERIMENTAL
Intervention: Blinatumomab (up to 5 cycles, continuous infusion, cycle: 4 weeks on/2 weeks off)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 110
Study: 34979115

Group type: EXPERIMENTAL
Intervention: MAGUS (Magnetic Gastrointestinal Universal Septotome) system
Number of subjects: 14
Study: 34979117

Group type: EXPERIMENTAL
Intervention: Colonoscopy retraction score (CoRS)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Withdrawal time
Number of subjects: 333
Study: 34979118

Group type: EXPERIMENTAL
Intervention: High-resolution manometry (HRM)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Functional lumen imaging probe (FLIP)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Eckardt score (ES)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Maximum esophagogastric junction distensibility (MxEGJD)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Normal post-POEM EGJ distensibility index (EGJ-DI)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Normal IRP
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Normal MxEGJD
Number of subjects: 87
Study: 34979601

Group type: EXPERIMENTAL
Intervention: Frozen section biopsy
Number of subjects: 646

Group type: COMPARATOR
Intervention: Frozen section biopsy omission
Number of subjects: 646